TC Biopharm Announces Special Dividend: Key Insights from 6-K Report

Here are the key insights extracted from the provided 6-K financial report for TC Biopharm (Holdings) PLC:

1. Special Dividend Announcement:

• Date of Announcement: December 18, 2024
• Dividend: The Board approved a special dividend of 0.25 American Depositary Shares (ADSs) for every 1 ADS held, pending shareholder approval.
• Expected Declaration Date: December 30, 2024
• Record Date for Shareholders: January 2, 2025
• Expected Payment Date: On or about January 6, 2025

2. Shareholder Approval:

• The shareholders approved the special dividend on December 30, 2024.

3. Trading Suspension:

• Due to the distribution of the dividend, Nasdaq will temporarily halt trading of the Company’s ADSs at the close of trading on January 2, 2025.
• Trading is expected to resume at the opening on January 8, 2025, accompanied by a price adjustment to reflect the dilution from the dividend.

4. Company Information:

• Name: TC Biopharm (Holdings) PLC
• Address: Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, Scotland, United Kingdom
• Contact Number: +44 (0) 141 433 7557

5. Regulatory Compliance:

• The report is filed as per the requirements of the Securities Exchange Act of 1934.

6. Signatory Information:

• The document is signed by Martin Thorp, Chief Financial Officer of TC Biopharm (Holdings) PLC, on December 31, 2024.

These points summarize the essential information regarding the company's financial actions and regulatory compliance.